RXi Pharmaceuticals Appoints Robert Bitterman and Keith Brownlie to Board of Directors

Published: Jun 21, 2012

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors. Mr. Bitterman and Mr. Brownlie both bring extensive industry experience that will be instrumental to supporting RXi’s growth and development initiatives.

Back to news